CYP Stock Overview
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.20 |
| 52 Week High | AU$0.34 |
| 52 Week Low | AU$0.12 |
| Beta | 0.94 |
| 1 Month Change | -5.88% |
| 3 Month Change | -4.76% |
| 1 Year Change | 66.67% |
| 3 Year Change | -58.33% |
| 5 Year Change | -80.68% |
| Change since IPO | -95.65% |
Recent News & Updates
Recent updates
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Sep 21
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?
May 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11Shareholder Returns
| CYP | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 11.1% | 0.1% | -2.7% |
| 1Y | 66.7% | 3.1% | 6.5% |
Return vs Industry: CYP exceeded the Australian Biotechs industry which returned 4.3% over the past year.
Return vs Market: CYP exceeded the Australian Market which returned 7.8% over the past year.
Price Volatility
| CYP volatility | |
|---|---|
| CYP Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: CYP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CYP's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| CYP fundamental statistics | |
|---|---|
| Market cap | AU$36.14m |
| Earnings (TTM) | -AU$9.74m |
| Revenue (TTM) | AU$2.32m |
15.6x
P/S Ratio-3.7x
P/E RatioIs CYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYP income statement (TTM) | |
|---|---|
| Revenue | AU$2.32m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.32m |
| Other Expenses | AU$12.06m |
| Earnings | -AU$9.74m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.054 |
| Gross Margin | 100.00% |
| Net Profit Margin | -420.82% |
| Debt/Equity Ratio | 0% |
How did CYP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:11 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cynata Therapeutics Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Chris Kallos | MST Financial Services Pty Limited |